News

Search:

Advisory Committee Votes Against Label Expansion for J&J/Bayer's Xarelto

0 Likes

The US Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee voted against Johnson & Johnson and Bayer’s co-developed oral anticoagulant drug Xarelto (rivaroxaban), Read More...

Tags:

ACS

Advisory Committee

Against

Bayer

Cardiovascular

FDA

J&J

Janssen

Nissen

Temple

Vote

Xarelto

Reviewers Express Doubts in Advance of Xarelto Review

0 Likes

An advisory committee to the US Food and Drug Administration (FDA) gave US-based manufacturer Johnson & Johnson’s (J&J) blood thinner Xarelto (rixaroxaban), experimentally used to treat acute coronary Read More...

Tags:

ACS

Advisory Committee

Bayer

Cardiovascular and Renal Drugs Committee

Data

drug

FDA

Heart

Hicks

J&J

Pharmaceutical

Xarelto

RF Today is Regulatory Focus' daily news brief. Each edition contains the top global regulatory news stories about pharmaceuticals, medical devices, biotechnology and more. Learn more

Most Viewed
Most Popular

Most Viewed

Public Warms to FDA in Recent Gallup Poll 28 May 2013
FDA Finalizes Changes to Orphan Drug Regulation, With Emphasis on Clarifying Existing Policies 11 June 2013
Warning Letter to Company Cites Low Supplies of Toilet Paper 15 May 2013
New FDA Document Clarifies IND Process for Drugs, Biologics and Biosimilars 30 April 2013
Interview: FDA's UDI Architect Jay Crowley on the Agency's Approach to UDI and Pending Changes 2 May 2013
IBM Awarded Huge Contract to Modernize Regulatory Review Processes at FDA 29 April 2013
New Legislation Seeks Creation of Provisional Approval Pathway for New Drugs 23 May 2013
New FDA Draft Guidance Aims to Clarify Compassionate Use Process 9 May 2013

New Regulatory Focus Apps for iPad and iPhone

Stay Connected:

Regulatory Focus is for regulatory professionals written by regulatory professionals.

The publication takes a look at the important topics facing regulatory professionals in a changing global healthcare landscape. From topics ranging from research and development to labeling and marketing, the articles try to analyze, inform, and educate readers about the issues at the forefront of the industry.

Rated as the number one benefit by the members of RAPS, Regulatory Focus strives to provide the best and most current information to regulatory professionals so they can succeed and advance at every stage in their careers.

For questions or comments on our content or to find out more about Regulatory Focus, please visit our About RF page.

News

Advisory Committee Votes Against Label Expansion for J&J/Bayer's Xarelto

Reviewers Express Doubts in Advance of Xarelto Review

Get RF Today